gc-tbc-logo

all-logos

The Grand Challenges in TB Control (GC-TBC) Program (www.gc-tbc.com) is an initiative to identify innovations, fund and nurture them to reach the field to help some of the critical challenges related to Tuberculosis. The program was made possible with support from funding partners; the United States Agency for International Development (USAID), the Bill & Melinda Gates Foundation, the Biotechnology Industry Research Assistance Council (BIRAC) (part of Govt. of India) and Department for International Development (DFID-UK), and implementation partner IKP Knowledge Park. It is also supported by the National TB Program (RNTCP) for pilot testing the innovations and experts from academia, hospitals and corporate as mentors.

Three different challenges were identified in combating the bane of TB in India and other developing countries. The first was that of treatment adherence given the long duration of the treatment regimen. The second problem was that of quick and accurate screening and detection of TB and MDR/XDR-TB. The third problem to be addressed were the gaps in the Public Private Partnership Systems.

GC-TBC Call I: Treatment Adherence for TB
Launch: May, 2013
Supported by: USAID & BMGF
Proposals Received: 122
Proposals funded for Call I Phase I: 13
Call I Phase I funding: US$ 30,000 (INR 20 Lakh) each
Proposals funded for Call I Phase II: 4
Call I Phase II funding: US$ 100,000 (INR 60 Lakh) each

GC-TBC Call II: TB Screening, Detection, and Diagnostics
Launch: June, 2015
Supported by: USAID & BIRAC
Proposals Received: 91
Proposals funded for Call II Phase I: 6
Call II Phase I funding: US$ 90,000 (INR 50 Lakh) each
Proposals funded for Call II Phase II: 4
Call II Phase II funding: US$ 2200,000 (INR 1.5 Crore) each

GC-TBC Call III: Public-Private-Partnerships for TB Treatment
Launch:  December, 2015
Supported by: USAID & DFID
Proposals Received: 122
Proposals funded for Call III: 3
Call III funding: US$ 360,000 (INR 2.4 Crore) each

For a list of awardees and the outcomes, please click here.